# China NMPA Inspection - Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd. - July 21, 2020

Source: https://www.globalkeysolutions.net/records/china_inspection/guangxi-fucodisai-regenerative-medicine-engineering-co-ltd/5aff909b-3bd4-459f-b984-6046d429ade1
Source feed: China

> China NMPA unannounced inspection for Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd. published July 21, 2020. The Guangxi Zhuang Autonomous Region Drug Administration conducted unannounced inspections of nine cosmetics manufacturers between June and July 2020,

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement of the Results of Supervision and Inspection of Cosmetic Manufacturers in Guangxi Zhuang Autonomous Region (Issue 1, 2020)
- Company Name: Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd.
- Publication Date: 2020-07-21
- Product Type: cosmetics
- Summary: The Guangxi Zhuang Autonomous Region Drug Administration conducted unannounced inspections of nine cosmetics manufacturers between June and July 2020, as part of its 2020 supervision plan. Based on the "Key Points for Cosmetic Production License Inspection," the inspections identified various compliance issues across several companies, including Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd., Guangxi Wanhao Biotechnology Co., Ltd., Guangxi Yinghe Pharmaceutical Co., Ltd., Nanning Daxumei Cosmetics Co., Ltd., Guangxi Luxianna Biotechnology Development Co., Ltd., Guangxi Tianqi Cosmetics Co., Ltd., and Guangxi Wuzhou Tengxian Liangyou Medical and Health Products Co., Ltd.

Common violations included inadequate record-keeping for material usage, machine operations, employee training, and equipment maintenance. Issues also arose from improper storage and segregation of raw and packaging materials, lack of expiration date labeling, and using expired laboratory solutions or uncalibrated equipment. Furthermore, some companies exhibited discrepancies between their established quality management systems and actual practices, or failed to update quality manager licenses. Two companies, Ruifuxiang Pharmaceutical (Guangxi) Co., Ltd. and Wuzhou Yingbai Biotechnology Co., Ltd., were found to be non-operational, with one planning license cancellation.

In response, the Drug Administration mandated most companies to promptly rectify all identified deficiencies and submit detailed rectification reports. This initiative underscores the regulatory body's commitment to ensuring compliance and product quality within the cosmetics manufacturing sector.

Company: https://www.globalkeysolutions.net/companies/guangxi-fucodisai-regenerative-medicine-engineering-co-ltd/ab8705fc-ca1c-4fdd-8f80-aff0b89b8795